🇺🇸 FDA
Patent

US 8173134

ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them

granted A61KA61K45/06A61P

Quick answer

US patent 8173134 (ECD carboxy-terminal deletion FGFR4 fusion proteins and methods of producing them) held by Five Prime Therapeutics, Inc. expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K45/06, A61P, A61P1/02, A61P1/04